Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma

This phase III randomized, double-blind, placebo-controlled trial evaluates whether nanocrystalline megestrol acetate can reduce anorexia in patients with locally advanced nasopharyngeal carcinoma (NPC) undergoing concurrent chemoradiotherapy (CCRT). The study aims to confirm the clinical benefits of adding this agent to standard CCRT for improving appetite, quality of life, nutritional status, and survival outcomes.

Trial Details

NCT ID
NCT07796789
Phase
PHASE3
Sponsor
Sun Yat-sen University
Status
RECRUITING
Cancer Type
Nasopharyngeal Head and Neck Cancer
Interventions
  • Nanocrystalline Megestrol Acetate Oral Suspension
  • Placebo
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Changsha, China|28.19874,112.97087
  • Fuzhou, China|26.06139,119.30611

Key Eligibility Criteria

  • Newly diagnosed, histologically or cytologically confirmed non-keratinizing nasopharyngeal carcinoma, clinical stage II-III according to the Americ…
  • No prior radiotherapy to the primary tumor.
  • Induction chemotherapy may be administered at the investigator's discretion according to local guidelines.
  • Aged 18-70 years, male or female.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Nasopharyngeal Head and Neck Cancer Trials on Trialify →